CFDE Data Portal | Search ATP1A2

	Label	Description
	ATP1A2 Gene (Entity type)	ENSG00000018625 - ATPase Na+/K+ transporting subunit alpha 2
	ATP1A2 associations Collection (Entity type)	Associations for ATP1A2_associations
	ATP1A2 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	GSE265788 IDH1 inhibition RNA-Directed DNA Polymerase 3 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE138789 metformin 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE261563 CX-5461 6 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE148200 0 V 2 GEMCITABINE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE238213 dopamine 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE216043 cisplatin 7 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE165960 MEK inhibition 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS

ATP1A2

ENSG00000018625 - ATPase Na+/K+ transporting subunit alpha 2

ATP1A2 associations

Associations for ATP1A2_associations

ATP1A2 associations.tsv

A file from IDG as part of the Harmonizome project

GSE265788 IDH1 inhibition RNA-Directed DNA Polymerase 3 v 2 human dn

A Gene Set from LINCS

GSE138789 metformin 0 v 1 human up

A Gene Set from LINCS

GSE261563 CX-5461 6 v 1 human up

A Gene Set from LINCS

GSE148200 0 V 2 GEMCITABINE HUMAN UP

A Gene Set from LINCS

GSE238213 dopamine 1 v 0 human dn

A Gene Set from LINCS

GSE216043 cisplatin 7 v 0 human dn

A Gene Set from LINCS

GSE165960 MEK inhibition 0 v 1 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.